(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 45.39% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Mirum Pharmaceuticals's revenue in 2024 is $186,374,000.On average, 6 Wall Street analysts forecast MIRM's revenue for 2024 to be $14,894,132,874, with the lowest MIRM revenue forecast at $14,518,858,295, and the highest MIRM revenue forecast at $15,299,583,590. On average, 6 Wall Street analysts forecast MIRM's revenue for 2025 to be $20,250,350,226, with the lowest MIRM revenue forecast at $18,743,987,539, and the highest MIRM revenue forecast at $22,712,008,573.
In 2026, MIRM is forecast to generate $27,447,264,946 in revenue, with the lowest revenue forecast at $22,795,627,495 and the highest revenue forecast at $32,308,678,255.